Fennec Pharmaceuticals (FENC) Q3 2026 earnings review
Fennec's drug sales rise fast, and its profit doubles
Fennec Pharmaceuticals is turning its expanded sales force into rising drug sales and rapid profit growth. The maker of PEDMARK, a drug that prevents chemotherapy hearing loss, grew net product sales 56% from a year ago to $19.4 million. Because overhead stayed mostly fixed after legal disputes ended, EBITDA excluding one-offs more than doubled from last quarter to $5.8 million. Chief executive Jeff Hackman highlighted record patient enrollments, and strong cash collections lifted ending cash to $48.7 million, above what the company's own plan pointed to.
| PEDMARK net product sales | $19.4M +56% from a year ago; +13% from last quarter |
|---|---|
| EBITDA, excluding one-offs and stock pay | $5.8M $2.8M last quarter; $2.0M a year ago |
| Operating cash flow | $6.7M lifted ending cash to $48.7M |
| Cash runway outlook | Unchanged cash and projected sales fund current plan |
⚖️ Verdict: 🟢 Bullish
The story got better because the spring sales-force expansion is delivering both 13% quarterly sales growth and immediate profit leverage. Lower legal bills and steady overhead allowed most of the new revenue to turn into $6.7 million of operating cash flow, removing any balance-sheet strain. Two cautions remain: diluted share count jumped 37% from a year ago, and management still reports patient demand only as percentages without disclosing patient counts or a revenue target.
The question now is how much of the 56% product sales increase came from doctors prescribing more vials versus smaller rebate deductions between gross and net sales. Either the enlarged sales team is winning young-adult cancer clinics at that full pace, or unusually low discount reserves flattered the revenue line. The gross-to-net footnote table in the upcoming third-quarter Form 10-Q filing will tell.
🐂 Bull Case
Sales Team Expansion Keeps Quarterly Growth Above 13%
PEDMARK is Fennec Pharmaceuticals' drug for preventing hearing loss from cisplatin chemotherapy. Chief executive Jeff Hackman expanded the sales team earlier this year to reach more cancer clinics, especially those treating adolescent and young adult (AYA) patients.
In the second full quarter after that expansion, Fennec said its field force operated with "greater reach and frequency to engage healthcare providers". Demand grew across both existing clinics and new AYA accounts.
- Net product sales: $19.4 million, up 55.9% from a year ago and 13.2% from last quarter
- Patient program enrollments: up 23% from the second quarter
- Completed drug infusions: up 58% from the second quarter
Annual growth slowed from 77.8% in the second quarter because Fennec is now comparing against last autumn's big sales jump. The 13.2% quarterly gain proves clinic adoption is still rising, and infusions growing faster than enrollments shows more enrolled patients are finishing treatment.
What to watch: fourth-quarter net product sales. Fennec expects "the productivity curve will continue to increase through the fourth quarter of 2026 and into 2027", so another double-digit quarterly gain would confirm new territories are paying off.
Operating Leverage Doubles Cash Profit and Builds Cash
Fennec spent heavily in the first half of 2026 to hire sales reps and market PEDMARK, which kept profit small. Management argued that once the larger sales team was in place, mostly fixed overhead would allow new sales to flow straight into profit.
That cost leverage arrived in the third quarter. Operating profit swung to $4.7 million from a $0.2 million loss a year ago, and operating cash flow reached $6.7 million, lifting cash to $48.7 million.
- General and administrative expenses (overhead and legal costs): 20.0% of revenue, down 23.8 percentage points from a year ago
- Selling and marketing expenses: 51.3% of revenue, down 1.0 percentage point from a year ago
- EBITDA excluding one-offs and stock pay: $5.8 million, more than double last quarter's $2.8 million
General and administrative spending fell because of "lower legal and professional fees as select litigation activities concluded". By our math, cash operating costs dropped to $12.8 million from $13.7 million in the second quarter, though that remains above the $10.0–11.2 million quarterly pace implied by management's earlier $50 million full-year cost plan.
What to watch: fourth-quarter cash operating expenses. A drop toward $10 million would meet the full-year cost target and lift operating margins again.
Japanese Trial Data Backs Safe Use in Older Patients
The US regulator approved PEDMARK for children, so Fennec relies on medical guidelines and doctor-led studies to convince oncologists to prescribe it for teenagers and young adults. Doctors often ask whether the drug protects hearing without weakening chemotherapy in older patients.
Researchers presented detailed results from STS-J01, a Phase 2 clinical trial in Japan testing PEDMARK in children and young adults, at the International Society of Pediatric Oncology meeting. Hearing loss occurred in 24.0% of treated patients versus a 56.4% historical benchmark, and the data gave "reassuring clinical context regarding antitumor activity with delayed PEDMARK".
This matters because oncologists treating young adults want proof that delayed dosing does not shield tumors from chemotherapy. Positive Japanese data also supports Fennec's search for a licensing partner in Japan.
What to watch: peer-reviewed publication of the STS-J01 study and any Japanese licensing deal. A partnership would bring upfront cash and validate the drug outside western markets.
🐻 Bear Case
Fennec Still Hides Patient Counts and Revenue Targets
"Given the significant increase in demand that we are seeing quarter over quarter in 2026, we firmly believe in the sustainable growth potential of PEDMARK," Hackman said. Yet the specialty drugmaker still gives investors no hard patient numbers and no revenue outlook.
For the third quarter, Fennec reported that program enrollments rose 23% and completed infusions rose 58% from the second quarter, and noted a record backlog of planned infusions entering October. Management did not disclose the actual number of patients, vials sold, active prescribing clinics, or the revenue split between children and young adults.
Percentage gains without base numbers make it impossible to tell whether growth comes from many clinics adopting the drug or higher prices and fewer discounts on a small patient pool. Refusing to issue a fourth-quarter revenue target despite claiming record planned infusions cuts against management's confidence in predictable demand.
What to watch: the third-quarter Form 10-Q filing. Its footnote table showing gross product sales versus price discounts will reveal how much of the 55.9% sales growth came from real volume versus lower rebate deductions.
Share Dilution and Option Grants Eat Into Per-Share Gains
Fennec raised equity late last year to pay off its debt and fund its larger sales force, and it rewards employees heavily with stock options. Those extra shares mean per-share earnings grow much more slowly than company profit.
The diluted share count reached 38.1 million in the third quarter, up 36.5% from 27.9 million a year ago and up 4.5% from 36.4 million in the second quarter. Stock-based compensation cost $1.4 million this quarter and $4.1 million over the first nine months of 2026, equal to 60% of nine-month net income.
What to watch: diluted share count and new option grants in the fourth quarter. Continued quarterly rises above 4% would keep shifting the gains from PEDMARK's growth away from existing shareholders.
European Rollout Slows to a Trickle
In March 2024, Fennec licensed European, UK, Australian and New Zealand rights for its drug (sold there as PEDMARQSI) to Norgine Pharmaceuticals. When Fennec ships drug vials to Norgine, it works down an upfront contract liability and records non-cash "other revenue".
That non-cash revenue dropped to $183 thousand in the third quarter from $710 thousand in the second quarter, so the total Norgine contract liability edged down by just $183 thousand to $23.9 million by our math. The release made no mention of European sales milestones, showing that international shipments remain lumpy and immaterial compared to US sales.
What to watch: fourth-quarter Norgine contract liability drawdowns. A second quarter below $200 thousand would indicate European commercial uptake has stalled.
Risks this quarter didn't answer
Three standing risks from prior quarters depend on footnote disclosures or long-term timelines that the third-quarter earnings release did not address.
- Gross-to-net price discounts: rebates and discounts dropped to 7.2% of gross sales in the first half of 2026 from 15.4% a year earlier; the third-quarter Form 10-Q revenue footnote will show whether discounts rose back toward historical levels.
- Distributor credit losses: the second-quarter filing carried a $6.3 million allowance for credit losses against trade receivables; the third-quarter Form 10-Q credit-risk footnote will show whether overdue distributor balances grew.
- Single-drug reliance: all revenue still comes from PEDMARK, whose US orphan exclusivity expires in September 2029 before settled generic entry in September 2033.
💲 Other KPIs
Collection timing improved this quarter. Current net accounts receivable — money owed by drug distributors — rose just 2.2% from last quarter to $23.8 million, while non-current receivables fell from $2.8 million at year-end to $2.0 million. Because total revenue grew 9.7% over the same three months, faster cash collections helped lift operating cash flow to $6.7 million.
Manufacturing profit stayed above 95% of revenue for a fourth straight quarter. Cost of product sales — the direct cost of making and packaging PEDMARK vials — was $838 thousand, or 4.3% of total revenue, down from 5.3% a year ago. That 1.0 percentage point improvement added to the company's operating leverage.
🔮 Guidance
Unchanged. Fennec reiterated that its $48.7 million cash balance and projected PEDMARK sales are "sufficient to fund our business based on our current operating plan". With zero debt and $6.7 million in quarterly operating cash flow, the specialty drugmaker added $7.4 million to its cash balance in the third quarter despite previously indicating on its second-quarter call that cash would dip.
❓ Key Questions
Did lower rebates or vial volume drive sales growth?
Discounts and allowances dropped to 7.2% of gross sales in the first half of 2026 from 15.4% a year earlier. Investors need the third-quarter gross product sales and discount figures to see whether net sales grew faster than actual vial demand.
How many patients and clinics use PEDMARK today?
Fennec reported a 23% quarterly rise in enrollments and a 58% rise in completed infusions, but never gives base numbers. Without active patient counts or the revenue split between children and young adults, outsiders cannot size market penetration.
Will full-year cash operating costs exceed $50 million?
By our math, nine-month cash operating expenses reached $40.1 million after a $12.8 million third quarter. Meeting the $50 million full-year target from prior calls would require fourth-quarter cash costs to drop by nearly $3 million.
Why did Norgine shipments slow in the third quarter?
Non-cash revenue from shipping vials to European partner Norgine fell from $710 thousand in the second quarter to $183 thousand in the third. Management has not explained the order slowdown or updated the timeline for European sales milestones.